NCT04199026 2026-02-19
Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent Sarcoma
M.D. Anderson Cancer Center
Phase NA Recruiting
Clinical Trials
11 trialsNCT03114527 2025-04-04
Phase II Trial of Ribociclib and Everolimus in Advanced Dedifferentiated Liposarcoma (DDL) and Leiomyosarcoma (LMS)
Fox Chase Cancer Center
Phase 2 Active not recruiting
NCT01275222 2021-06-25
Everolimus in Combination With Imatinib in Patients With Glivec Refractory/Resistant Gastrointestinal Stromal Tumors
Novartis
Phase 1/2 Completed
NCT01661283 2019-03-06
SARC016: Study of Everolimus With Bevacizumab to Treat Refractory Malignant Peripheral Nerve Sheath Tumors
Sarcoma Alliance for Research through Collaboration
Phase 2 Completed
NCT01804374 2015-06-17
SERIO
Italian Sarcoma Group
Phase 2 Completed
NCT00187174 2015-03-04
Everolimus for Treating Pediatric Patients With Recurrent or Refractory Tumors
St. Jude Children's Research Hospital
Phase 1 Completed
NCT01281865 2014-10-08
Everolimus in Combination With Imatinib Mesylate in Treating Patients With Locally Advanced, Locally Recurrent, or Metastatic Soft Tissue Sarcoma
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT01048723 2013-12-16
Study of RAD001 in Soft Tissue Extremity and/or Retroperitoneal Sarcomas
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Terminated
NCT00927966 2013-11-14
RAD001 in Combination With CP-751,871 in Patients Wtih Advanced Sarcomas and Other Malignant Neoplasms
Dana-Farber Cancer Institute
Phase 1 Completed
NCT01830153 2013-04-12
RAD001 in Advanced Sarcoma
Asan Medical Center
Phase 2 Completed
NCT01216839 2013-03-26
Phase II Study of Everolimus in Children and Adolescents With Refractory or Relapsed Rhabdomyosarcoma and Other Soft Tissue Sarcomas
Hospital Santa Marcelina
Phase 2 Unknown